Samiksha Jaiswal (Editor)

Noopept

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
CAS Number  157115-85-0
ChemSpider  157065
Formula  C17H22N2O4
PubChem CID  180496
3D model (Jmol)  Interactive image
Molar mass  318.367 g/mol
Noopept
Legal status  US: Unscheduled Not FDA approved
Synonyms  N-Phenylacetyl-L-prolylglycine ethyl ester

Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl--prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia.

Contents

Noopept review a simplified overview


Mechanism of action

Technically, Noopept is not a racetam, due to not having a 2-oxo-pyrrolidine skeleton, but is generally grouped together in the same category because it shares similar mechanisms of action with the racetam family, mainly modulation of the acetylcholine system, as well as modulation of AMPA receptors. When compared to traditional racetams, it has been found to be active at 1/1000th of the dose of the prototypical racetam drug, piracetam. Noopept is a prodrug for the endogenous peptide cycloprolylglycine, which means that Noopept isn't active until metabolized into cycloprolylglycine.

Pharmacokinetics

Peak plasma noopept concentrations of 13-33 μg/L are reached within one hour after a single 20 mg oral dose. The half-life averages about 1 hour in healthy individuals. It is mainly cleared renally as a series of metabolites produced by amide and ester hydrolysis, deacylation and aromatic hydroxylation. Noopept may be quantitated in biofluids by liquid chromatography with one of several different detection techniques.

References

Noopept Wikipedia


Similar Topics
Rita Rani Ahuja
Bob Mensch
Shin Min a
Topics
 
B
i
Link
H2
L